OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.toxicon.2017.08.026 | DOI Listing |
Publication Analysis
Top Keywords
chronic migraine
8
botulinum toxin
4
toxin chronic
4
migraine clinical
4
clinical trials
4
trials technical
4
technical aspects
4
aspects onabotulinumtoxina
4
onabotulinumtoxina approved
4
approved prophylaxis
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!